Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
- Author:
Christopher P GUISE
1
;
Alexandra M MOWDAY
;
Amir ASHOORZADEH
;
Ran YUAN
;
Wan-Hua LIN
;
Dong-Hai WU
;
Jeff B SMAILL
;
Adam V PATTERSON
;
Ke DING
Author Information
- Publication Type:Journal Article
- MeSH: Anthraquinones; chemistry; pharmacology; Antineoplastic Agents; chemistry; pharmacology; Aziridines; chemistry; pharmacology; Cell Hypoxia; drug effects; Humans; Indolequinones; chemistry; pharmacology; Molecular Structure; NAD(P)H Dehydrogenase (Quinone); chemistry; pharmacology; Neoplasms; drug therapy; pathology; Nitrogen Mustard Compounds; chemistry; pharmacology; Nitroimidazoles; chemistry; pharmacology; Phosphoramide Mustards; chemistry; pharmacology; Prodrugs; chemistry; pharmacology; Triazines; chemistry; pharmacology
- From:Chinese Journal of Cancer 2014;33(2):80-86
- CountryChina
- Language:English
- Abstract: Hypoxia, a state of low oxygen, is a common feature of solid tumors and is associated with disease progression as well as resistance to radiotherapy and certain chemotherapeutic drugs. Hypoxic regions in tumors, therefore, represent attractive targets for cancer therapy. To date, five distinct classes of bioreactive prodrugs have been developed to target hypoxic cells in solid tumors. These hypoxia-activated prodrugs, including nitro compounds, N-oxides, quinones, and metal complexes, generally share a common mechanism of activation whereby they are reduced by intracellular oxidoreductases in an oxygen-sensitive manner to form cytotoxins. Several examples including PR-104, TH-302, and EO9 are currently undergoing phase II and phase III clinical evaluation. In this review, we discuss the nature of tumor hypoxia as a therapeutic target, focusing on the development of bioreductive prodrugs. We also describe the current knowledge of how each prodrug class is activated and detail the clinical progress of leading examples.
